| Nivolumab plus ipilimumab in advanced melanoma JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ... New England Journal of Medicine 369 (2), 122-133, 2013 | 4976 | 2013 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3071 | 2019 |
| Immunotherapy in colorectal cancer: rationale, challenges and potential K Ganesh, ZK Stadler, A Cercek, RB Mendelsohn, J Shia, NH Segal, ... Nature reviews Gastroenterology & hepatology 16 (6), 361-375, 2019 | 1218 | 2019 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1052 | 2017 |
| Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ... Journal of Clinical Oncology 34 (26), 3119, 2016 | 894 | 2016 |
| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 766 | 2022 |
| Clinical sequencing defines the genomic landscape of metastatic colorectal cancer R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ... Cancer cell 33 (1), 125-136. e3, 2018 | 678 | 2018 |
| Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ... Journal of clinical oncology 37 (4), 286, 2019 | 494 | 2019 |
| Adoption of total neoadjuvant therapy for locally advanced rectal cancer A Cercek, CSD Roxburgh, P Strombom, JJ Smith, LKF Temple, GM Nash, ... JAMA oncology 4 (6), e180071-e180071, 2018 | 494 | 2018 |
| Epitope landscape in breast and colorectal cancer NH Segal, DW Parsons, KS Peggs, V Velculescu, KW Kinzler, ... Cancer research 68 (3), 889-892, 2008 | 483 | 2008 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 436 | 2019 |
| Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy JJ Smith, P Strombom, OS Chow, CS Roxburgh, P Lynn, A Eaton, ... JAMA oncology 5 (4), e185896-e185896, 2019 | 436 | 2019 |
| Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial PJ Bergman, J McKnight, A Novosad, S Charney, J Farrelly, D Craft, ... Clinical Cancer Research 9 (4), 1284-1290, 2003 | 435 | 2003 |
| Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor VR Belum, B Benhuri, MA Postow, MD Hellmann, AM Lesokhin, NH Segal, ... European journal of cancer 60, 12-25, 2016 | 430 | 2016 |
| CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit J Yuan, S Gnjatic, H Li, S Powel, HF Gallardo, E Ritter, GY Ku, ... Proceedings of the National Academy of Sciences 105 (51), 20410-20415, 2008 | 406 | 2008 |
| Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody NH Segal, TF Logan, FS Hodi, D McDermott, I Melero, O Hamid, ... Clinical Cancer Research 23 (8), 1929-1936, 2017 | 375 | 2017 |
| Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy J Garcia-Aguilar, S Patil, MJ Gollub, JK Kim, JB Yuval, HM Thompson, ... Journal of clinical oncology 40 (23), 2546, 2022 | 373 | 2022 |
| Cross-presentation of disialoganglioside GD3 to natural killer T cells DY Wu, NH Segal, S Sidobre, M Kronenberg, PB Chapman The Journal of experimental medicine 198 (1), 173-181, 2003 | 368 | 2003 |
| EWS-CREB1: a recurrent variant fusion in clear cell sarcoma—association with gastrointestinal location and absence of melanocytic differentiation CR Antonescu, K Nafa, NH Segal, P Dal Cin, M Ladanyi Clinical Cancer Research 12 (18), 5356-5362, 2006 | 311 | 2006 |
| Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1 J Naidoo, K Schindler, C Querfeld, K Busam, J Cunningham, DB Page, ... Cancer immunology research 4 (5), 383-389, 2016 | 265 | 2016 |
